{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T14:40:02Z","timestamp":1722523202838},"reference-count":0,"publisher":"Wiley","issue":"B","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:p>Physicians should try to achieve an optimal cure rate with their initial\n<jats:italic>Helicobacter pylori<\/jats:italic> eradication therapy. Most physicians use the\nsame treatment in all their patients. <jats:italic>H pylori<\/jats:italic> infection in patients\nwith peptic ulcer disease (PUD) is more likely to be cured than that\nin patients with functional dyspepsia (FD). Differences in cure rates\nof 5% to 15% are usually reported, which is considered to be clinically\nrelevant. A plausible biological explanation for this finding suggests\nthat different strains (virulent [<jats:italic>cagA<\/jats:italic>+, <jats:italic>vacA<\/jats:italic> type s1] compared\nwith nonvirulent strains [<jats:italic>cagA<\/jats:italic>\u2013, <jats:italic>vacA<\/jats:italic> type s2]) in PUD and FD\ninduce different changes in the gastric mucosa, and this facilitates or\nimpairs antimicrobial efficacy. Physicians should be aware that most\npublished treatment studies have included only PUD patients. This\nmeans that in clinical practice cure rates obtained in patients with\nFD or perhaps uninvestigated dyspepsia are usually lower than those\nreported in the literature. This has implications for the choice of\ntreatment. Physicians should consider prolonging the duration of initial\n<jats:italic>Helicobacter<\/jats:italic> eradication therapy from seven to 10 to 14 days in\npatients without ulcers.<\/jats:p>","DOI":"10.1155\/2003\/136716","type":"journal-article","created":{"date-parts":[[2016,5,16]],"date-time":"2016-05-16T21:00:44Z","timestamp":1463432444000},"update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eradication Therapy Should Be Different for Dyspeptic Patients than for Ulcer Patients"],"prefix":"10.1155","volume":"17","author":[{"given":"Wink A","family":"de Boer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,1]]},"container-title":["Canadian Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjgh\/2003\/136716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2003\/136716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T14:14:36Z","timestamp":1722521676000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2003\/136716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":0,"journal-issue":{"issue":"B","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1155\/2003\/136716"],"URL":"https:\/\/doi.org\/10.1155\/2003\/136716","archive":["Portico"],"relation":{},"ISSN":["2291-2789","2291-2797"],"issn-type":[{"type":"print","value":"2291-2789"},{"type":"electronic","value":"2291-2797"}],"subject":[],"published":{"date-parts":[[2003,1]]},"assertion":[{"value":"2003-01-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}